Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Global Blood Therapeutics Shares Tick Higher After Pfizer Buy Agreed

Published 08/08/2022, 09:43 AM
Updated 08/08/2022, 09:47 AM
© Reuters

© Reuters

By Scott Kanowsky 

Investing.com -- Pfizer Inc (NYSE:PFE) has agreed to acquire California-based Global Blood Therapeutics Inc (NASDAQ:GBT) for $5.4B including debt and net of cash acquired, as the U.S. drugmaker looks to expand its pipeline of offerings by using a glut of cash built up from the sale of Covid-19 vaccines.

The transaction, which has been unanimously approved by the boards of both companies, will see Pfizer acquire all the outstanding shares of GBT for $68.40 per share in cash - a 7.3% premium on GBT's closing share price on Friday.

GBT specializes in treatments for a blood disorder known as sickle cell disease that impacts up to 100,000 people in the U.S.

“The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible,” said Pfizer chairman and chief executive officer Albert Bourla in a statement.

Pfizer added that it plans to boost sales of GBT's Oxbryta sickle cell disease drug. It will also bring GBT's oral sickle hemoglobin polymerization inhibitor, now in Phase 2 trials, into its portfolio.

GBT becomes the latest acquisition target bagged by Pfizer, who has gone on a buying spree recently partly due to the widespread usage of the Covid vaccine it developed with German peer BioNTech.

This year, Pfizer has bought biotech firms Biohaven Pharmaceuticals and Arena Pharmaceuticals for $11.6B and $6.7B, respectively. The moves are expected to bolster the variety of treatments Pfizer can offer going forward as sales of Covid medicines are expected to slow following the pandemic.

NASDAQ-listed shares in GBT surged by more than 4% in early U.S. trading on Monday, adding to gains last week made when the Wall Street Journal first reported Pfizer was in talks to buy the company.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.